Zentalis Pharmaceuticals ... (ZNTL)
NASDAQ: ZNTL
· Real-Time Price · USD
1.56
-0.08 (-4.88%)
At close: Aug 19, 2025, 11:54 AM
-4.88% (1D)
| Bid | 1.56 |
| Market Cap | 112.89M |
| Revenue (ttm) | 26.86M |
| Net Income (ttm) | -224.19M |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -0.69 |
| Forward PE | -0.66 |
| Analyst | Hold |
| Ask | 1.57 |
| Volume | 390,829 |
| Avg. Volume (20D) | 959,932 |
| Open | 1.61 |
| Previous Close | 1.64 |
| Day's Range | 1.56 - 1.66 |
| 52-Week Range | 1.01 - 5.44 |
| Beta | 1.72 |
About ZNTL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZNTL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZNTL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-21.25%
Zentalis Pharmaceuticals shares are trading lower....
Unlock content with
Pro Subscription
7 months ago
-1.08%
Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA has granted Fast Track Designation to azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
